34
Peripheral T-Cell Lymphomas: How I Manage Frontline Disease CHOP clearly inferior, but is a regulatory standard. Integrating etoposide may provide advantage? Caution removal of doxorubicin based upon the T-cell Lymphoma Project Consolidation with ASCT probably beneficial, and more so then in the relapsed or refractory setting Allogeneic stem cell transplant should be considered in eligible patients with R/R disease USE NEWER FDA APPROVED DRUGS earlier in the natural history of the disease. Many new studies emerging as CHOP additions (Pralatrexate, Romidepsin, Brentuximab vedotin, Belinostat)